HB 0036
Alternative Names: Anti-PD-L1; anti-TIGIT bifunctional molecule; HB-0036Latest Information Update: 16 Jul 2024
At a glance
- Originator Huabo Biopharm
- Class Antineoplastics
- Mechanism of Action Programmed cell death-1 ligand-1 modulators; TIGIT protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 30 Aug 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent) in USA (IV, Infusion) (NCT05417321)
- 05 Jul 2021 Preclinical trials in Solid tumours in China (Unspecified route)